Research Report University Hospital for clinical assessment GO27826

Abstract

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence

Keywords

• Surgically Resected, Cutaneous BRAF Mutant Melanoma
• vemurafenib (RO5185426)